You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lueckerath K, Bailis J, Current K, et al
717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0717